http://www.kangantu.org/tumour/80321.html Web2024年5月7日,美国FDA加速批准MET抑制剂Capmatinib(卡马替尼,商品名Tabrecta)上市,用于治疗携带MET基因外显子14跳跃突变的晚期非小细胞 肺癌 (NSCLC)。. Capmatinib是一种针对MET的激酶抑制剂,包括外显子14跳跃产生的突变体。. MET外显子14跳过会导致蛋白质缺失 ...
A Safety and Efficacy Study of INC280 Alone, and in Combination …
WebMay 25, 2024 · 9509 Background: In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, capmatinib (INC280) has shown efficacy in METex14–mutated NSCLC patients (pts) who were pretreated (cohort 4) or treatment (tx)-naïve (cohort 5b). Here, we report the efficacy and safety of capmatinib in pts with high-level MET-amplified (gene copy number … WebMay 15, 2024 · Capmatinib (INC280, formerly INCB28060) is a highly selective and potent MET inhibitor with in vitro and in vivo activities against preclinical cancer models with MET activation . Capmatinib is being tested both as a single agent and in combination in multiple clinical trials that are guided by biomarker-based patient selection criteria. ion op
Study of EGF816 in Combination With Selected Targeted Agents in …
WebJan 12, 2015 · The purpose of this study is to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of nazartinib (EGF816) in combination with capmatinib (INC280) and to estimate the preliminary anti-tumor activity of nazartinib in combination with capmatinib in participants with advanced non-small cell lung cancer (NSCLC) with ... WebJan 15, 2024 · INC280卡马替尼的效果作用非常良好; INC280卡马替尼可使MET-14外显子突变非小细; INC280卡马替尼对MET的高水平扩增具有中等; Fda批准卡马替尼captatinib用 … WebFeb 20, 2024 · 随着微阵列、RNA-seq和高通量测序(HTS)技术的出现,每天都在产生大量的生物医学数据,因此当代药物发现已经过渡到大数据时代。. 在药物发现中,第一步也是最重要的一步是确定与疾病病理生理学相关的适当靶点(例如基因、蛋白质),然后找到可以干 … on the clearwater